

# Effects of butyrate compared to donor faeces transplantation on metabolism and satiety in patients with metabolic syndrome

Gepubliceerd: 01-08-2014 Laatste bijgewerkt: 18-08-2022

Intestinal bacteria have been linked to human metabolism. Animal studies have suggested that the intestinal microbiota product butyrate itself can also affect satiety and improves insulin sensitivity. The question thus remains whether increasing...

|                             |                       |
|-----------------------------|-----------------------|
| <b>Ethische beoordeling</b> | Positief advies       |
| <b>Status</b>               | Werving gestopt       |
| <b>Type aandoening</b>      | -                     |
| <b>Onderzoekstype</b>       | Interventie onderzoek |

## Samenvatting

### ID

NL-OMON26960

### Bron

Nationaal Trial Register

### Verkorte titel

APPETITE study

### Aandoening

insulin resistance, overweight, gutmicrobiota

### Ondersteuning

**Primaire sponsor:** AMC-uvA

**Overige ondersteuning:** EU FP7

### Onderzoeksproduct en/of interventie

## Uitkomstmaten

### Primaire uitkomstmaten

- Insulin sensitivity and lipolysis (2-step hyperinsulinemic euglycemic clamp)<br>
- Hypothalamic (SPECT-scan), small intestinal (biopsy) and urinal (24h urine sample) serotonin levels in relation to satiety testing

## Toelichting onderzoek

### Achtergrond van het onderzoek

In this RCT we aim to dissect whether intestinal microbiota or their product butyrate affect human (serotonin) driven satiety and insulin resistance in humans.

### Doel van het onderzoek

Intestinal bacteria have been linked to human metabolism. Animal studies have suggested that the intestinal microbiota product butyrate itself can also affect satiety and improves insulin sensitivity. The question thus remains whether increasing intestinal levels of butyrate itself has the same metabolic effects as increasing levels of intestinal butyrate-producing bacterial strains. We therefore aim to compare the effects of oral butyrate vs donor fecal transplantation on insulin sensitivity, intestinal transit time and serotonin mediated satiety in treatment naive patients with insulin resistance.

### Onderzoeksopzet

0 and 4 weeks

### Onderzoeksproduct en/of interventie

allogenic healthy (postbariatric surgery) donor feces transplantation + placebo tablets for 4 weeks VERSUS autologous fecal transplantation + sodium butyrate tablets for 4 weeks

## Contactpersonen

### Publiek

AFDELING INWENDIGE GENEESKUNDE AMC<br>MEIBERGDREEF 9, KAMER F4.159.2

M. Nieuwdorp  
Amsterdam 1105 AZ  
The Netherlands  
+31 (0)20 5666612

## Wetenschappelijk

AFDELING INWENDIGE GENEESKUNDE AMC  
MEIBERGDREEF 9, KAMER F4.159.2  
M. Nieuwdorp  
Amsterdam 1105 AZ  
The Netherlands  
+31 (0)20 5666612

## Deelname eisen

### Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

- Caucasian male or postmenopausal female
- 50-70 years old
- BMI  $\geq 30$  kg/m<sup>2</sup>
- At least 3 out of 5 NCEP metabolic syndrome criteria: fasting plasma glucose  $\geq 5.6$  mmol/l, triglycerides  $\geq 1.7$  mmol/l, waist-circumference  $> 102$  cm, HDL-cholesterol  $1.04$  mmol/l, blood pressure  $\geq 130/85$  mmHg
- Subjects should be able and willing to give informed consent

### Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)

- Any Medication use, including PPI and antibiotics in last 3 months
- Drug abuse
- Alcohol abuse ( $> 3$ /day)
- Participation in a research protocol involving radiation exposure in the last 2 years.

- eGFR <60 ml/min
- Contraindication for MRI (claustrophobia)
- History of cardiovascular event (MI or pacemaker implantation)
- Cholecystectomy
- Expected prolonged compromised immunity (due to recent cytotoxic chemotherapy or HIV infection with a CD4 count < 240)

## Onderzoeksopzet

### Opzet

|                  |                       |
|------------------|-----------------------|
| Type:            | Interventie onderzoek |
| Onderzoeksmodel: | Parallel              |
| Toewijzing:      | Gerandomiseerd        |
| Blindering:      | Dubbelblind           |
| Controle:        | Placebo               |

### Deelname

|                         |                       |
|-------------------------|-----------------------|
| Nederland               |                       |
| Status:                 | Werving gestopt       |
| (Verwachte) startdatum: | 01-09-2014            |
| Aantal proefpersonen:   | 24                    |
| Type:                   | Werkelijke startdatum |

## Ethische beoordeling

|                 |                  |
|-----------------|------------------|
| Positief advies |                  |
| Datum:          | 01-08-2014       |
| Soort:          | Eerste indiening |

## Registraties

### Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

### Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

### In overige registers

| Register       | ID           |
|----------------|--------------|
| NTR-new        | NL4488       |
| NTR-old        | NTR4713      |
| Ander register | : MEC 14/084 |

## Resultaten